Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This therapeutic combination is a multi-component formulation designed for the symptomatic management of gastroesophageal reflux disease (GERD) and gastric hyperacidity. It operates through a triple mechanism of action: sodium alginate reacts with gastric acid to form a physical 'raft' or barrier that floats on top of the stomach contents, mechanically preventing the reflux of acid and bile into the esophagus. Calcium carbonate and magnesium carbonate act as antacids, neutralizing excess gastric acidity to provide rapid relief from heartburn. Additionally, hyaluronic acid and aloe vera provide a muco-protective effect by coating the esophageal and gastric mucosa, shielding the tissue from chemical irritation and facilitating the healing of acid-induced damage. The product is typically administered as an oral tablet designed to dissolve in the mouth to maximize mucosal contact.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium alginate + calcium carbonate + magnesium carbonate + hyaluronic acid + aloe vera.